Table analysing the proposed measures in the Draghi Report for the space sector. It is based on seven variabes distributed in columns. The first three are ranking variables where each measure is awarded a score relative to the other measures in its sector or subsector in a hierarchical way: urgency in the EU, importance of the measure for the EU and importance of the measure for Spain. The remaining four variables classify the proposals on the basis of a three-point scale that depends on the assessment of the proposed measure itself: presence in the Mission Letters (explicit reference, ambiguous or no mention at all), political viability for the EU and for Spain (high, medium or low), and level of public investment needed to put the measure in practice (high-susbtantial, medium-little or none-nothing). Draghi puts forward nine measures for the pharmaceutical sector. A third of these are classified as Political Wins: expediting access to markets with coordinated action (111), clear guidelines on the use of AI in the sector (112) and improving business predictability through dialogue with the relevant stakeholders (114). Maximising the impact of the EU Health Data Space (109) constitutes a Quick Win. The investment needs in the pharmaceutical sector are divided evenly: a third of the measures require substantial investment, a third moderate and another third little investment.